Literature DB >> 8866830

Substituted flavones as aryl hydrocarbon (Ah) receptor agonists and antagonists.

Y F Lu1, M Santostefano, B D Cunningham, M D Threadgill, S Safe.   

Abstract

The structure-dependent aryl hydrocarbon (Ah) receptor agonist and antagonist activities of the following substituted flavones were investigated: flavone, 4'-methoxy-, 4'-amino-, 4'-chloro-, 4'-bromo-, 4'-nitro-, 4'-chloro-3'-nitro-, 3'-amino-4'-hydroxy-, 3',4'-dichloro-, and 4'-iodoflavone. The halogenated flavones exhibited competitive Ah receptor binding affinities (IC50 = 0.79 to 2.28 nM) that were comparable to that observed for 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) (1.78 nM). The compounds also induced transformation of the rat cytosolic Ah receptor and induced CYP1A1 gene expression in MCF-7 human breast cancer cells. However, despite the high Ah receptor binding affinities for these responses, the halogenated flavones were > 1000 times less active than TCDD for the other responses. Moreover, for other substituted flavones, there was no correlation between Ah receptor binding affinities and their activities as Ah receptor agonists. For example, 4'-aminoflavone induced CYP1A1 mRNA levels in MCF-7 cells but exhibited relatively low Ah receptor binding affinity (IC50 = 362 nM) and did not induce transformation of the rat cytosolic Ah receptor. All of the substituted flavones inhibited TCDD-induced transformation of the Ah receptor, and 4'-iodoflavone, an Ah receptor agonist at high concentrations (1-50 microM), inhibited the transformation at concentrations as low as 0.05 and 0.5 microM. Subsequent interaction studies with TCDD and 4'-iodoflavone confirmed that the latter compound inhibits induction of CYP1A1 gene expression by TCDD in MCF-7 cells. The results obtained for the substituted flavones suggest that within this structural class of compounds, various substituent groups can affect markedly the activity of each individual congener as an Ah receptor agonist or antagonist. These substituent-dependent differences in activity may be related to ligand-induced conformational changes in the Ah receptor complex and/or support the proposed existence of more than one form of the Ah receptor.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8866830     DOI: 10.1016/0006-2952(96)00063-9

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  18 in total

Review 1.  Ah receptor ligands and their impacts on gut resilience: structure-activity effects.

Authors:  Stephen Safe; Arul Jayaraman; Robert S Chapkin
Journal:  Crit Rev Toxicol       Date:  2020-06-29       Impact factor: 5.635

2.  Novel 2-amino-isoflavones exhibit aryl hydrocarbon receptor agonist or antagonist activity in a species/cell-specific context.

Authors:  Richard J Wall; Guochun He; Michael S Denison; Cenzo Congiu; Valentina Onnis; Alwyn Fernandes; David R Bell; Martin Rose; J Craig Rowlands; Gianfranco Balboni; Ian R Mellor
Journal:  Toxicology       Date:  2012-04-07       Impact factor: 4.221

3.  Aryl Hydrocarbon Receptor Activity of Tryptophan Metabolites in Young Adult Mouse Colonocytes.

Authors:  Yating Cheng; Un-Ho Jin; Clint D Allred; Arul Jayaraman; Robert S Chapkin; Stephen Safe
Journal:  Drug Metab Dispos       Date:  2015-04-14       Impact factor: 3.922

4.  In silico identification of an aryl hydrocarbon receptor antagonist with biological activity in vitro and in vivo.

Authors:  Ashley J Parks; Michael P Pollastri; Mark E Hahn; Elizabeth A Stanford; Olga Novikov; Diana G Franks; Sarah E Haigh; Supraja Narasimhan; Trent D Ashton; Timothy G Hopper; Dmytro Kozakov; Dimitri Beglov; Sandor Vajda; Jennifer J Schlezinger; David H Sherr
Journal:  Mol Pharmacol       Date:  2014-08-26       Impact factor: 4.436

5.  Microbiome-derived tryptophan metabolites and their aryl hydrocarbon receptor-dependent agonist and antagonist activities.

Authors:  Un-Ho Jin; Syng-Ook Lee; Gautham Sridharan; Kyongbum Lee; Laurie A Davidson; Arul Jayaraman; Robert S Chapkin; Robert Alaniz; Stephen Safe
Journal:  Mol Pharmacol       Date:  2014-02-21       Impact factor: 4.436

6.  Inhibition of the aryl hydrocarbon receptor/polyamine biosynthesis axis suppresses multiple myeloma.

Authors:  Anna Bianchi-Smiraglia; Archis Bagati; Emily E Fink; Hayley C Affronti; Brittany C Lipchick; Sudha Moparthy; Mark D Long; Spencer R Rosario; Shivana M Lightman; Kalyana Moparthy; David W Wolff; Dong Hyun Yun; Zhannan Han; Anthony Polechetti; Matthew V Roll; Ilya I Gitlin; Katerina I Leonova; Aryn M Rowsam; Eugene S Kandel; Andrei V Gudkov; P Leif Bergsagel; Kelvin P Lee; Dominic J Smiraglia; Mikhail A Nikiforov
Journal:  J Clin Invest       Date:  2018-09-10       Impact factor: 14.808

7.  Omeprazole Inhibits Pancreatic Cancer Cell Invasion through a Nongenomic Aryl Hydrocarbon Receptor Pathway.

Authors:  Un-Ho Jin; Sang-Bae Kim; Stephen Safe
Journal:  Chem Res Toxicol       Date:  2015-04-09       Impact factor: 3.739

Review 8.  Xenobiotic metabolism, disposition, and regulation by receptors: from biochemical phenomenon to predictors of major toxicities.

Authors:  Curtis J Omiecinski; John P Vanden Heuvel; Gary H Perdew; Jeffrey M Peters
Journal:  Toxicol Sci       Date:  2010-11-08       Impact factor: 4.849

9.  Molecular determinants of species-specific agonist and antagonist activity of a substituted flavone towards the aryl hydrocarbon receptor.

Authors:  E C Henry; T A Gasiewicz
Journal:  Arch Biochem Biophys       Date:  2008-02-13       Impact factor: 4.013

10.  Modeling of the aryl hydrocarbon receptor (AhR) ligand binding domain and its utility in virtual ligand screening to predict new AhR ligands.

Authors:  William H Bisson; Daniel C Koch; Edmond F O'Donnell; Sammy M Khalil; Nancy I Kerkvliet; Robert L Tanguay; Ruben Abagyan; Siva Kumar Kolluri
Journal:  J Med Chem       Date:  2009-09-24       Impact factor: 7.446

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.